0
0
12/19/22 at 11:02pm
Organization
Medscape
31 words
0
Comments
The expanded indication for pafolacianine (Cytalux) follows an initial approval in November 2021 for use in patients with ovarian cancer.
You are the first to view
https://www.medscape.com/viewarticle/985847
Create an account
or login to join the discussion